Comparison of the ecarin chromogenic assay and different aPTT assays for the measurement of argatroban concentrations in plasma from healthy individuals and from coagulation factor deficient patients

Thrombosis Research

Volumn 123, Issue 1, 2008, Pages 159-165

  Siegmund, Robert ^a   Boer, Klas ^a   Poeschel, Katrin ^a   Wolf, Gunter ^a   Deufel, Thomas ^a   Kiehntopf, Michael ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

aPTT; Argatroban; DTI; ECA; ECT

Indexed keywords

ARGATROBAN; ECARIN; PHENPROCOUMON;

ARTICLE; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TEST; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MONITORING; ECARIN CHROMOGENIC ASSAY; HUMAN; INTERMETHOD COMPARISON; LIVER DYSFUNCTION; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; QUALITY CONTROL;

ANTICOAGULANTS; COAGULATION PROTEIN DISORDERS; ENDOPEPTIDASES; HUMANS; PARTIAL THROMBOPLASTIN TIME; PIPECOLIC ACIDS; QUALITY CONTROL;

EID: 54049156150     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2008.02.013     Document Type: Article

References (34)

1. Lewis B.E., Wallis D.E., Berkowitz S.D., Matthai W.H., Fareed J., Walenga J.M., Bartholomew J., Sham R., Lerner R.G., Zeigler Z.R., Rustagi P.K., Jang I.K., Rifkin S.D., Moran J., Hursting M.J., and Kelton J.G. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 103 14 (Apr 10 2001) 1838-1843
2. Lewis B.E., Wallis D.E., Leya F., Hursting M.J., and Kelton J.G. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 163 15 (Aug 11-25 2003) 1849-1856
3. Jeske W.P., and Walenga J.M. Antithrombotic drugs for the treatment of heparin-induced thrombocytopenia. Methods Mol Med 93 (2004) 61-82
4. Matthai Jr. W.H., Hursting M.J., Lewis B.E., and Kelton J.G. Argatroban anticoagulation in patients with a history of heparin-induced thrombocytopenia. Thromb Res 116 2 (2005) 121-126
5. Warkentin T.E. Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban. Thromb Res 110 2-3 (May 1 2003) 73-82
6. Levine R.L., Hursting M.J., and McCollum D. Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction. Chest 129 5 (May 2006) 1167-1175
7. Kaplan K.L. Direct thrombin inhibitors. Expert Opin Pharmacother 4 5 (May 2003) 653-666
8. Kathiresan S., Shiomura J., and Jang I.K. Argatroban. J Thromb Thrombolysis 13 1 (Feb 2002) 41-47
9. Di Nisio M., Middeldorp S., and Buller H.R. Direct thrombin inhibitors. N Engl J Med 353 10 (Sep 8 2005) 1028-1040
10. Swan S.K., and Hursting M.J. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 20 3 (Mar 2000) 318-329
11. Hursting M.J., Alford K.L., Becker J.C., Brooks R.L., Joffrion J.L., Knappenberger G.D., Kogan P.W., Kogan T.P., McKinney A.A., and Schwarz Jr. R.P. Novastan (brand of argatroban): a small-molecule, direct thrombin inhibitor. Semin Thromb Hemost 23 6 (1997) 503-516
12. Gray E., and Harenberg J. Collaborative study on monitoring methods to determine direct thrombin inhibitors lepirudin and argatroban. J Thromb Haemost 3 9 (Sep 2005) 2096-2097
13. Walenga J.M., Fasanella A.R., Iqbal O., Hoppensteadt D.A., Ahmad S., Wallis D.E., and Bakhos M. Coagulation laboratory testing in patients treated with argatroban. Semin Thromb Hemost 25 Suppl 1 (1999) 61-66
14. Francis J.L., and Hursting M.J. Effect of argatroban on the activated partial thromboplastin time: a comparison of 21 commercial reagents. Blood Coagul Fibrinolysis 16 4 (Jun 2005) 251-257
15. Swan S.K., St Peter J.V., Lambrecht L.J., and Hursting M.J. Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects. Pharmacotherapy 20 7 (Jul 2000) 756-770
16. Harenberg J., Jorg I., Fenyvesi T., and Piazolo L. Treatment of patients with a history of heparin-induced thrombocytopenia and anti-lepirudin antibodies with argatroban. J Thromb Thrombolysis 19 1 (Feb 2005) 65-69
17. Beiderlinden M., Treschan T.A., Gorlinger K., and Peters J. Argatroban anticoagulation in critically ill patients. Ann Pharmacother 41 5 (May 2007) 749-754
18. Bartholomew J.R., Pietrangeli C.E., and Hursting M.J. Argatroban anticoagulation for heparin-induced thrombocytopenia in elderly patients. Drugs Aging 24 6 (2007) 489-499
19. Love J.E., Ferrell C., and Chandler W.L. Monitoring direct thrombin inhibitors with a plasma diluted thrombin time. Thromb Haemost 98 1 (Jul 2007) 234-242
20. Choi T.S., Khan A.I., Greilich P.E., and Kroll M.H. Modified plasma-based ecarin clotting time assay for monitoring of recombinant hirudin during cardiac surgery. Am J Clin Pathol 125 2 (Feb 2006) 290-295
21. Lange U, Nowak G, Bucha E. Ecarin chromogenic assay-a new method for quantitative determination of direct thrombin inhibitors like hirudin. Pathophysiol Haemost Thromb 2003 Jul-2004 Aug;33(4):184-91.
22. Potzsch B., Hund S., Madlener K., Unkrig C., and Muller-Berghaus G. Monitoring of recombinant hirudin: assessment of a plasma-based ecarin clotting time assay. Thromb Res 86 5 (Jun 1 1997) 373-383
23. Nowak G. Clinical monitoring of hirudin and direct thrombin inhibitors. Semin Thromb Hemost 27 5 (Oct 2001) 537-541
24. Fenyvesi T., Jorg I., and Harenberg J. Monitoring of anticoagulant effects of direct thrombin inhibitors. Semin Thromb Hemost 28 4 (Aug 2002) 361-368
25. Hafner G., Roser M., and Nauck M. Methods for the monitoring of direct thrombin inhibitors. Semin Thromb Hemost 28 5 (Oct 2002) 425-430
26. Harder S., Graff J., Klinkhardt U., von Hentig N., Walenga J.M., Watanabe H., Osakabe M., and Breddin H.K. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time. Thromb Haemost 91 6 (Jun 2004) 1137-1145
27. Fenyvesi T., Jorg I., Weiss C., and Harenberg J. Effects of lepirudin, argatroban and melagatran and additional influence of phenprocoumon on ecarin clotting time. Thromb Res 111 1-2 (2003) 89-94
28. Desmet V.J., Gerber M., Hoofnagle J.H., Manns M., and Scheuer P.J. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology (Baltimore, Md.) 19 6 (Jun 1994) 1513-1520
29. Wayne P. National Committee for Clinical Laboratory Standards. Evaluation of the linearity of quantitative analytical methods; proposed guideline EP6-P. NCCLS (1986)
30. Orfeo T., Brufatto N., Nesheim M.E., Xu H., Butenas S., and Mann K.G. The factor V activation paradox. J biol Chem 279 19 (May 7 2004) 19580-19591
31. Mann K.G., Brummel K., and Butenas S. What is all that thrombin for?. J Thromb Haemost 1 7 (Jul 2003) 1504-1514
32. Bajaj S.P., Rapaport S.I., and Brown S.F. Isolation and characterization of human factor VII. Activation of factor VII by factor Xa. J Biol Chem 256 1 (Jan 10 1981) 253-259
33. Yeh R.W., and Jang I.K. Argatroban: update. Am Heart J Jun 151 6 (2006) 1131-1138
34. Antman E.M. Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. Circulation 90 4 (Oct 1994) 1624-1630